Inactive Instrument

Orphée SA Stock

Equities

ORP

CH0197761098

Advanced Medical Equipment & Technology

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Dynamic Chart
PZ Cormay S.A. acquired unknown minority stake in Orphée SA for CHF 1.2 million. CI
PZ Cormay S.A. completed the acquisition of 0.54% stake in Orphée SA for PLN 0.37 million. CI
PZ Cormay S.A. made a tender offer to acquire remaining 2.9% stake in Orphée SA for PLN 2 million. CI
PZ Cormay S.A. agreed to acquire remaining 11.6% stake in Orphée SA for PLN 7.8 million. CI
MED II, managed by ArchiMed SAS completed the acquisition of DIESSE Diagnostica Senese S.p.A. from Orphée SA and founders for €14.5 million. CI
Orphée Is In Talks To Sell Stake In DIESSE CI
MED II, managed by ArchiMed SAS signed a letter of intent to acquire DIESSE Diagnostica Senese S.p.A. from Orphée SA and founders. CI
PZ Cormay S.A. cancelled the acquisition of an additional 12.95% stake in Orphée SA from TTL 1 SP Z O O. CI
PZ Cormay S.A. signed an agreement to acquire additional 12.95% stake in Orphée SA from TTL 1 SP Z O O for PLN 10 million. CI
Orphée SA completed the acquisition of TT Management sp. z o.o. from Planezza SA. CI
Tadeusz Tuora sold 6.6% stake in Orphée SA for PLN 2.1 million. CI
Tranche Update on Orphée SA's Equity Buyback Plan announced on February 23, 2015. CI
Orphée SA's Equity Buyback announced on February 26, 2015, has expired with repurchase of 3,859,118 shares, for PLN 34.3 million. CI
TTL 1 SP Z O O and another shareholder completed the acquisition of 27% stake in Orphée SA from PZ Cormay S.A.. CI
TTL 1 SP Z O O and another shareholder agreed to acquire 27% stake in Orphée SA from PZ Cormay S.A. for PLN 20.8 million. CI
More news
Members of the board TitleAgeSince
Director/Board Member - 14-12-31
Director/Board Member 47 -
More insiders
Orphee SA is a Switzerland-based company engaged in development and marketing of instrumentation for the haematology diagnostics. The Company operates in over 100 countries worldwide, including Brazil, Bangladesh, China, Philippines, Mexico, Romania, Poland, among others, and is primarily engaged in in-vitro diagnostics (IVD) market. It divides its business into three segments: Sale and Production of Haematology and Electrolyte Analyzers, offering six types of analyzers under the name Mythic (Mythic 18, Mythic 18 Vet, Mythic 22 OT, Mythic 22 CT, Mythic 22 AL, Mythic Lyte); Sale and Production of Blood Test Reagents, and Sale of Spare Parts for Offered Analyzers. The Company is a subsidiary of PZ Cormay SA. On September 1, 2014, the Company acquired 100% stake in TT Management Sp z o o to enable execution of the restructuring plan of Cormay group which aims at transferring production and distribution activity of Cormay group to Orphee.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW